Drug Profile

Trastuzumab rezetecan - Jiangsu HengRui Medicine Co

Alternative Names: SHR-A1811

Latest Information Update: 01 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Developer Fudan University; Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Registered Non-small cell lung cancer
Phase III Adenocarcinoma; Breast cancer; Colorectal cancer; HER2 positive breast cancer; Ovarian cancer
Phase II Biliary cancer; Gynaecological cancer; Salivary gland cancer
Phase I/II Solid tumours

20 Jun 2025 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University plans phase II trial for Breast cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in Jun 2025 (Parental) (NCT07037199)
04 Jun 2025 Phase-II clinical trials in Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV), before June 2025 (Jiangsu HengRui Medicine Co pipeline, June 2025)
04 Jun 2025 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in China (IV), before June 2025 (Jiangsu HengRui Medicine Co pipeline, June 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com